Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers

Journal of Clinical Oncology

Volumn 14, Issue 2, 1996, Pages 497-502

  Nishio, M ^a   Koshikawa, T ^a   Kuroishi, T ^a   Suyama, M ^a   Uchida, K ^a   Takagi, Y ^a   Washimi, O ^a   Sugiura, T ^a   Ariyoshi, Y ^a   Takahashi, T ^a,a   Ueda, R ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOLOGY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 9044231367     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.2.497     Document Type: Article

References (30)

1. Statistics and Information Department: Vital Statistics 1990 Japan, vol 1. Tokyo, Japan, Ministry of Health and Welfare, 1991, pp 96-97
2. Minna JD, Pass H, Glatstein E, et al: Lung Cancer, in DeVita VT, Rosenberg S, Hellman S (eds): Principles and Practice of Oncology. Philadelphia, PA, Lippincott, 1989, pp 591-705
3. Minna JD, Nau M, Takahashi T, et al: Molecular pathogenesis of lung cancer, in Bergsagel DE, Mak TW (ed): Molecular Mechanisms and Their Clinical Applications in Malignancies. Orlando, FL, Academic, 1991, pp 63-83
4. Takahashi T, Nau MM, Chiba I, et al: p53: A frequent target for genetic abnormalities in lung cancer. Science 246:491-494, 1989
5. Takahashi T, Takahashi T, Suzuki H, et al: The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 6:1775-1778, 1991
6. Takahashi T, Carbone D, Takahashi T, et al: Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 52:2340-2343, 1992
7. Suzuki H, Takahashi T, Kuroishi T, et al: p53 mutations in non-small cell lung cancer in Japan: Association between mutations and smoking. Cancer Res 52:734-736, 1992
8. Quinlan DC, Davidson AG, Summers CL, et al: Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52:4828-4831, 1992
9. McLaren R, Kuzu I, Dunnill M, et al: The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66:735-738, 1992
10. Horio Y, Takahashi T, Kuroishi T, et al: Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell cancer. Cancer Res 53:1-4, 1993
11. Brambilla E, Gazzeri S, Moro D, et al: Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 143:199-210, 1993
12. Mitsudomi T, Oyama T, Kusano T, et al: Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst 85:2018-2023, 1993
13. Ebina M, Steinberg SM, Mulshine JL, et al: Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 54:2496-2503, 1994
14. Carbone DP, Mitsudomi T, Chiba I, et al: p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. Chest 106:377S-381S, 1994 (suppl)
15. Matsuda R, Takahashi T, Nakamura S, et al: Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am J Pathol 142:339-346, 1993
16. World Health Organization: WHO Histological Typing of Lung Tumors (ed 2). Geneva, Switzerland, World Health Organization, 1981
17. Mountain CF: A new international staging system for lung cancer. Chest 89:225-233, 1986 (suppl)
18. Passlick B, Izbicki J, Riethmüller G, et al: p53 in non-small cell lung cancer. J Natl Cancer Inst 86:801-802, 1994 (letter)
19. Horio Y, Suzuki H, Ueda R, et al: Predominantly tumor-limited expression of a mutant allele in a Japanese family carrying a germline p53 mutation. Oncogene 9:1231-1235, 1994
20. Barnes DM, Hanby AM, Gillett CE, et al: Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 340:259-263, 1992
21. Bennett WP, Colby TV, Travis WD, et al: p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res 53:4817-4822, 1993
22. Shimosato Y, Noguchi M, Matsuno Y: Adenocarcinoma of the lung: Its development and malignant progression. Lung Cancer 9:99-108, 1993
23. McGuire WL: Breast cancer prognostic factors: Evaluation guidelines. J Natl Cancer Inst 83:154-155, 1991 (editorial)
24. Levine MN, Browman GP, Gent M, et al: When is a prognostic factor useful?: A guide for the perplexed. J Clin Oncol 9:348-356, 1991 (editorial)
25. Weston A, Willey J, Modali R, et al: Differential DNA sequence deletions from chromosomes 3, 11, 13, and 17 in squamous-cell carcinoma, large-cell carcinoma adenocarcinoma of the human lung. Proc Natl Acad Sci USA 86:5099-5103, 1989
26. Chiba I, Takahashi T, Nau M, et al: Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5:1603-1610, 1990
27. Sato S, Nakamura Y, Tsuchiya E: Difference of allelotype between squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res 54:5652-5655, 1994
28. Sundaresan V, Ganly P, Hasleton P, et al: p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene 7:1989-1997, 1992
29. Baker SJ, Preisinger AC, Jessup JM, et al: p53 gene mutations occur in combination with 17p deletions as late events in colorectal tumorigenesis. Cancer Res 50:7717-7722, 1990
30. Sidransky D, Mikkelsen T, Schwechheimer K, et al: Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355:846-847, 1992